nach oben

Digestive Diseases and Sciences

Erschienen in:

01.12.2014 | Review

Tachykinin Peptide, Substance P, and Its Receptor NK-1R Play an Important Role in Alimentary Tract Mucosal Inflammation During Cytotoxic Therapy

verfasst von: P. S. Satheeshkumar, Minu P. Mohan

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The alimentary tract mucosal inflammation has been a topic of concern in oncology; though many modalities of treatment have been proposed for mucosal inflammation, the contributing adverse effects have severely affected the quality of life of patients. This review focuses on the importance of neurogenic peptide, Substance P and its receptor NK-1R in modulating the cascades of events in mucosal inflammation during cytotoxic therapy. There are various preclinical and clinical models showing increased expression of Substance P/NK-1R in ionizing radiation and chemotherapy, but only very few preclinical studies to our knowledge have highlighted or examined its role in mucosal inflammation. Hence, the importance of neuropeptide involved in the inflammatory events in mucosal inflammation in cytotoxic therapy could be a major breakthrough for future research purposes and treatment. The factors contributing to the severity of tissue reactions have been multietiogenic; thus, resultant treatment also has to be directed toward multiple contributing factors. This review also focuses on the significance of care strategy to be adopted in alimentary tract mucositis when multietiogenic factors are taken into consideration.

Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110–1120.PubMedCrossRef

Kim JW, Cha Y, Kim SJ, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20:395–403.PubMedCrossRef

Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Cancer. 2008;113:2704–2713.CrossRef

Sonis ST. Oral mucositis in head and neck cancer. Am Soc Clin Oncol Educ Book. 2013;2013:236–240.CrossRef

Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2:21–32.PubMed

Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163–171.PubMedCrossRef

Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:1188–1198.PubMedCrossRef

Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013;21:2075–2083.PubMedCrossRef

Matsumoto K, Nakajima T, Sakai H, et al. Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. Dig Dis Sci. 2013;58:3440–3451.PubMedCrossRef

10.

Höckerfelt U, Franzén L, Kjörell U, Forsgren S. Parallel increase in substance P and VIP in rat duodenum in response to irradiation. Peptides. 2000;21:271–281.PubMedCrossRef

11.

Höckerfelt U, Franzén L, Forsgren S. Substance P (NK1) receptor in relation to substance P innervation in rat duodenum after irradiation. Regul Pept. 2001;98:115–126.PubMedCrossRef

12.

Forsgren S, Höckerfelt U, Norrgård O, Henriksson R, Franzén L. Pronounced substance P innervation in irradiation-induced enteropathy—a study on human colon. Regul Pept. 2000;88:1–13.PubMedCrossRef

13.

Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–4119.PubMedCrossRef

14.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–3098.PubMedCrossRef

15.

Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–2830.PubMedCrossRef

16.

Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci. 2006;1088:23–40.PubMedCrossRef

17.

Gerard NP, Garraway LA, Eddy RL Jr, et al. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry. 1991;30:10640–10646.PubMedCrossRef

18.

Harrison S, Geppetti P. Substance p. Int J Biochem Cell Biol. 2001;33:555–576.PubMedCrossRef

19.

Datar P, Srivastava S, Coutinho E, Govil G. Substance P: structure, function, and therapeutics. Curr Top Med Chem. 2004;4:75–103.PubMedCrossRef

20.

O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol. 2004;201:167–180.PubMedCrossRef

21.

González Moles MA, Esteban F, Ruiz-Avila I, et al. A role for the substance P/NK-1 receptor complex in cell proliferation and apoptosis in oral lichen planus. Oral Dis. 2009;15:162–169.

22.

Evangelista S. Involvement of tachykinins in intestinal inflammation. Curr Pharm Des. 2001;7:19–30.PubMedCrossRef

23.

Carter MS, Krause JE. Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma. J Neurosci. 1990;10:2203–2214.PubMed

24.

Zhang Y, Lu L, Furlonger C, Wu GE, Paige CJ. Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis. Nat Immunol. 2000;1:392–397.PubMedCrossRef

25.

Dornan WA, Vink KL, Malen P, Short K, Struthers W, Barrett C. Site-specific effects of intracerebral injections of three neurokinins (neurokinin A, neurokinin K, and neurokinin gamma) on the expression of male rat sexual behavior. Physiol Behav. 1993;54:249–258.PubMedCrossRef

26.

Duffy RA, Hedrick JA, Randolph G, et al. Centrally administered Hemokinin-1 (HK-1), a neurokinin NK1 receptor agonist, produces substance P-like behavioral effects in mice and gerbils. Neuropharmacology. 2003;45:242–250.PubMedCrossRef

27.

Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34:39–43.PubMedCrossRef

28.

Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025.PubMedCrossRef

29.

Sonis ST. The biologic role for nuclear factor-kappa B in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13:380–389.PubMedCrossRef

30.

Logan RM, Gibson RJ, Sonis ST, Keefe DMK. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43:395–401.PubMedCrossRef

31.

Sonis ST. Oral mucositis. Anticancer Drugs. 2011;22:607–612.PubMedCrossRef

32.

Kozakiewicz M, Godlewski A. Modulation of the mitotic activity and population of the mast cells in the oral mucosa by substance P. Cell Mol Biol Lett. 2003;8:727–734.PubMed

33.

Aalto Y, Forsgren S, Kjörell U, Franze´n L, Gustafsson H, Henriksson R. Time- and dose-related changes in the expression of substance P in salivary glands in response to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1995;33:297–305.

34.

Forsgren S, Franzén L, Funegård U, Gustafsson H, Henriksson R. Bilateral irradiation of head and neck induces an enhanced expression of substance P in the parasympathetic innervation of the submandibular gland. Neuroscience 1992;46:233–240.

35.

Lidegran M, Domeij S, Dalqvist Å, et al. Irradiation influences the expression of substance P and enkephalin in the rat larynx. Cell Tissue Res. 1995;279:55–63.PubMedCrossRef

36.

Alfieri AB, Cubeddu LX. Efectos de los antagonistas de los receptors NK1 y de la dexametasona sobre la inflamación neurogénica inducida porciclofosfamida y por radiación X, en la rata. AVFT. 2004;23:61–66.

37.

Goode T, O’Connell J, Sternini C, et al. Substance P (neurokinin-1) receptor is a marker of human mucosal but not peripheral mononuclear cells: molecular quantitation and localization. J Immunol. 1998;161:2232–2240.PubMed

38.

Pothoulakis C, Castagliuolo I, Leeman SE, et al. Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. Am J Physiol. 1998;275:G68–G75.PubMed

39.

Andrews PLR, Rudd JA. The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Hofmann FB, ed. Handbook of experimental pharmacology. Berlin: Springer; 2004:359–440.

40.

González Moles MA, Mosqueda-Taylor A, Esteban F et al. Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours. Oral Oncol. 2008; 44:1127–1133.

41.

Kabashima H, Nagata K, Maeda K, Iijima T. Involvement of substance P, mast cells, TNF-alpha and ICAM-1 in the infiltration of inflammatory cells in human periapical granulomas. J Oral Pathol Med. 2002;31:175–180.PubMedCrossRef

42.

Cocchiara R, Albeggiani G, Azzolina A, et al. Effect of Substance P on uterine mast cell cytokine release during the reproductive cycle. J Neuroimmunol. 1995;60:107–115.PubMedCrossRef

43.

Cocchiara R, Bongiovanni A, Albeggiani G, et al. Inhibitory effect of neuraminidase on SP-induced histamine release and TNF-α mRNA: evidence of a receptor-independent mechanism. J Neuroimmunol. 1997;75:9–18.PubMedCrossRef

44.

Kaltschmidt B, Baeuerle PA, Kaltschmidt C. Potential involvement of the transcription factor NF-kappa B in neurological disorders. Mol Aspects Med. 1993;14:171–190.PubMedCrossRef

45.

Azzolina A, Bongiovanni A, Lampiasi N. Substance P induces TNF-alpha and IL-6 production through NF kappa B in peritoneal mast cells. Biochim Biophys Acta Mol Cell Res. 2003;1643:75–83.CrossRef

46.

Cocchiara R, Bongiovanni A, Albeggiani G, Azzolina A, Geraci D. Substance P selectively activates TNF-alpha mRNA in rat uterine immune cells: a neuroimmune link. NeuroReport. 1997;8:2961–2964.PubMedCrossRef

47.

Azzolina A, Guarneri P, Lampiasi N. Involvement of p38 and JNK MAPKs pathways in substance P-induced production of the TNF-α by peritoneal mast cells. Cytokine. 2002;18:72–80.PubMedCrossRef

48.

Ishizuka T, Terada N, Gerwins P, et al. Mast cells tumor necrosis factor alpha production is regulated by MEK kinases. Proc Natl Acad Sci. 1997;94:6358–6363.PubMedCentralPubMedCrossRef

49.

Lorenz D, Wiesner B, Zipper J, et al. Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies. J Gen Physiol. 1998;112:577–591.PubMedCentralPubMedCrossRef

50.

Ferry X, Eichwald V, Daeffler L, Landry Y. Activation of betagamma subunits of G_i2 and G_i3 proteins by basic secretagogues induces exocytosis through phospholipases cβ and arachidonate release through phospholipase Cgamma in mast cells. J Immunol. 2001;167:4805–4813.PubMedCrossRef

51.

Page S, Fischer C, Baumgartner B, et al. 4-Hydroxynonenal prevents NFκB activation and tumor necrosis factor expression by inhibiting IκB phosphorylation and subsequent proteolysis. J Biol Chem. 1999;274:11611–11618.PubMedCrossRef

52.

Pelletier C, Varin-Blank N, Rivera J, et al. FcεRI-mediated induction of TNF-α gene expression in the RBL-2H3 mast cell line: regulation by a novel NFκB-like nuclear binding complex. J Immunol. 1998;161:4768–4776.PubMed

53.

Al-Dasooqi N, Gibson RJ, Bowen JM, Logan RM, Stringer AM, Keefe DM. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood). 2010;235:1244–1256.CrossRef

54.

Cury PR, Canavez F, de Araújo VC, Furuse C, de Araújo NS. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res. 2008;43:255–260.PubMedCrossRef

55.

Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem. 1999;274:30858–30863.PubMedCrossRef

56.

Zampetaki A, Mitsialis SA, Pfeilschifter J, Kourembanas S. Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/p44 and PI3 kinase pathways. FASEB J. 2004;18:1090–1092.PubMed

57.

Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37–40.PubMedCrossRef

58.

Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426–4441.PubMedCentralPubMedCrossRef

59.

Kefaloyianni E, Gaitanaki C, Beis I. ERK1/2 and p38-MAPK signalling pathways, through MSK1, are involved in NF-kappaB transactivation during oxidative stress in skeletal myoblasts. Cell Signal. 2006;18:2238–2251.PubMedCrossRef

60.

Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–869.PubMed

61.

Alarcon-Vargas D, Ronai Z. c-Jun-NH2 kinase (JNK) contributes to the regulation of c-Myc protein stability. J Biol Chem. 2004;279:5008–5016.PubMedCrossRef

62.

Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell. 2004;15:713–725.PubMedCrossRef

63.

Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100–3112.PubMedCrossRef

64.

Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev. 2012;92:689–737.PubMedCrossRef

65.

Chen Z, Gibson TB, Robinson F, et al. MAP kinases. Chem Rev. 2001;101:2449–2476.PubMedCrossRef

66.

Sun J, Ramnath RD, Zhi L, Tamizhselvi R, Bhatia M. Substance P enhances NF-kappaB transactivation and chemokine response in murine macrophages via ERK1/2 and p38 MAPK signaling pathways. Am J Physiol Cell Physiol. 2008;294:C1586–C1596.PubMedCrossRef

67.

Maes M, Lin AH, Delmeire L, et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry. 1999;45:833–839.PubMedCrossRef

68.

Powell ND, Tarr AJ, Sheridan JF. Psychosocial stress and inflammation in cancer. Brain Behav Immun. 2013;30:S41–S47.PubMedCrossRef

69.

Peters EM, Liotiri S, Bodo E, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol. 2007;171:1872–1886.PubMedCentralPubMedCrossRef

70.

Chancellor-Freeland C, Zhu GF, Kage R, Beller DI, Leeman SE, Black PH. Substance P and stress-induced changes in macrophages. Ann N Y Acad Sci. 1995;771:472–484.PubMedCrossRef

71.

Paus R, Heinzelmann T, Schultz KD, Furkert J, Fechner K, Czar-netzki BM. Hair growth induction by substance P. Lab Invest. 1994;71:134–140.PubMed

72.

Peters EM, Botchkarev VA, Botchkareva NV, Tobin DJ, Paus R. Hair-cycle-associated remodelling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. J Invest Dermatol. 2001;116:236–245.PubMedCrossRef

73.

Peters EM, Kuhlmei A, Tobin DJ, Muller-Rover S, Klapp BF, Arck PC. Stress exposure modulates peptidergic innervation and degranulates mast cells in murine skin. Brain Behav Immun. 2005;19:252–262.PubMedCrossRef

74.

Rice FL, Fundin B T, Arvidsson J, Aldskogius H, Johansson O. Comprehensive immunofluorescence and lectin binding analysis of vibrissal follicle sinus complex innervation in the mystacial pad of the rat. J Comp Neurol. 1997: 385:149–184.

75.

Arck PC, Handjiski B, Peters EM, et al. Stress inhibits hair growth in mice by induction of premature catagen development and deleterious perifollicular inflammatory events via neuropeptide substance P-dependent pathways. Am J Pathol. 2003;162:803–814.PubMedCentralPubMedCrossRef

76.

Raithel M, Schneider HT, Hahn EG. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol. 1999;34:496–503.PubMedCrossRef

77.

Mantyh PW, Catton M, Maggio JE, Vigna SR. Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. Adv Exp Med Biol. 1991;298:253–283.PubMedCrossRef

78.

Mazumdar S, Das KM. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol. 1992;87:176–181.PubMed

79.

Newson B, Dahlstrom A, Enerbäck L, Ahlman H. Suggestive evidence for a direct innervation of mucosal mast cells. Neuroscience. 1983;10:565–570.PubMedCrossRef

80.

Goyal RK, Hirano I. The enteric nervous system. N Engl J Med. 1996;334:1106–1115.PubMedCrossRef

81.

Farhadi A, Fields JZ, Keshavarzian A. Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation. World J Gastroenterol. 2007;13:3027–3030.PubMedCentralPubMed

82.

Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef

83.

He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol. 2004;10:309–318.PubMed

84.

Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463:235–272.PubMedCrossRef

85.

Schemann M. Control of gastrointestinal motility by the “gut brain”—the enteric nervous system. J Pediatr Gastroenterol Nutr. 2005;41:S4–S6.PubMedCrossRef

86.

Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 1995;345:99–103.PubMedCrossRef

87.

Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut. 2000;47:861–869.PubMedCentralPubMedCrossRef

88.

Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993;329:1246–1253.PubMedCrossRef

89.

Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut. 2005;54:1481–1491.PubMedCentralPubMedCrossRef

90.

Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy. 2001;56:928–936.PubMedCrossRef

91.

Ray A, Sehgal PB. Cytokines and their receptors: molecular mechanism of interleukin-6 gene repression by glucocorticoids. J Am Soc Nephrol. 1992;2:S214–S221.PubMed

92.

Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF- alpha release by macrophages. Inflamm Res. 2001;50:337–340.PubMedCrossRef

93.

Franchimont D, Kino T, Galon J, Meduri GU, Chorousos G. Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 2002–2003;10:247–260.

94.

Yamaguchi M, Takizawa T, Nakajima R, Imamura R, Kasai. The Damon System and release of substance P in gingival crevicular fluid during orthodontic tooth movement in adults. World J Orthod.. 2009;10:141–146.PubMed

95.

Caviedes-Bucheli J, Azuero-Holguin MM, Gutierrez-Sanchez L, et al. The effect of three different rotary instrumentation systems on substance P and calcitonin gene-related peptide expression in human periodontal ligament. J Endod. 2010;36:1938–1942.PubMedCrossRef

96.

Herpfer I, Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs. 2005;19:275–293.PubMedCrossRef

97.

Pike JL, Smith TL, Hauger RL, et al. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med. 1997;59:447–457.PubMedCrossRef

98.

Liu L, Markus I, Saghire HE, Perera DS, King DW, Burcher E. Gene expression in ulcerative colitis, Crohn’s disease and diverticular disease: a role for hemokinin-1? Neurogastroenterol Motil. 2011;23:475–483 (e179–1e80).

99.

Morse HR, Olomolaiye OO, Wood NA, Keen LJ, Bidwell JL. Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine. 1999;11:789–795.PubMedCrossRef

100.

Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis—where and how to look for it? Radiother Oncol. 2002;64:131–140.PubMedCrossRef

101.

Stringer AM. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients.. 2013;5:1488–1499.PubMedCentralPubMedCrossRef

102.

Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood).. 2009;234:430–441.PubMedCrossRef

103.

Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–284.PubMedCrossRef

104.

Graham GJ, Stevens JM, Page NM, et al. Tachykinins regulate the function of platelets. Blood. 2004;104:1058–1065.PubMedCrossRef

105.

Esteban F, Munoz M, Gonzalez-Moles MA, Rosso M. A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 2006;25:137–145.PubMedCrossRef

106.

Esteban F, Gonzalez-Moles MA, Castro D, et al. Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology. 2009;54:258–260.PubMedCrossRef

Titel: Tachykinin Peptide, Substance P, and Its Receptor NK-1R Play an Important Role in Alimentary Tract Mucosal Inflammation During Cytotoxic Therapy
verfasst von: P. S. Satheeshkumar
Minu P. Mohan
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 12/2014
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-014-3263-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Tachykinin Peptide, Substance P, and Its Receptor NK-1R Play an Important Role in Alimentary Tract Mucosal Inflammation During Cytotoxic Therapy

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Cholecystectomy for Biliary Dyskinesia: How Did We Get There?

Risk Factors for Serrated Polyps of the Colorectum

The Comparison of Two Different 5.5 Fr Sphincterotomes for Selective Cannulation of the Common Bile Duct: A Prospective, Randomized Study

Intent-to-Treat Analysis of Liver Transplant for Hepatocellular Carcinoma in the MELD Era: Impact of Hepatitis C and Advanced Status

Protective Effects of Garlic Extract, PMK-S005, Against Nonsteroidal Anti-inflammatory Drugs–Induced Acute Gastric Damage in Rats

Preconditioning with Intravenous Colitic Cell-Free DNA Prevents DSS-Colitis by Altering TLR9-Associated Gene Expression Profile

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin